Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.

Vitamin D insufficiency is common globally and low levels are linked to higher cancer incidence. Although vitamin D insufficiency is related to inferior prognosis in some cancers, no data exist for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We evaluated the relationship of 25(OH)D serum levels with time-to-treatment (TTT) and overall survival (OS) in newly diagnosed CLL patients participating in a prospective cohort study (discovery cohort) and a separate cohort of previously untreated patients participating in an observational study (confirmation cohort). Of 390 CLL patients in the discovery cohort, 119 (30.5%) were 25(OH)D insufficient. After a median follow-up of 3 years, TTT (hazard ratio[HR] = 1.66; P = .005) and OS (HR = 2.39; P = .01) were shorter for 25(OH)D-insufficient patients. In the validation cohort, 61 of 153 patients (39.9%) were 25(OH)D insufficient. After a median follow-up of 9.9 years, TTT (HR = 1.59; P = .05) and OS (HR 1.63; P = .06) were again shorter for 25(OH)D-insufficient patients. On pooled multivariable analysis of patients in both cohorts adjusting for age, sex, Rai stage, CD38 status, ZAP-70 status, immunoglobulin heavy chain variable (IGHV) gene mutation status, CD49d status, and cytogenetic abnormalities assessed by interphase fluorescent in situ hybridization testing, 25(OH)D insufficiency remained an independent predictor of TTT (HR = 1.47; P = .008), although the association with OS was not significant (HR = 1.47; P = .07). Vitamin D insufficiency is associated with inferior TTT and OS in CLL patients. Whether normalizing vitamin D levels in deficient CLL patients would improve outcome merits clinical testing.

[1]  W. Willett,et al.  American Journal of Epidemiology Original Contribution Circulating 25-hydroxyvitamin D and Risk of Non-hodgkin Lymphoma Cohort Consortium Vitamin D Pooling Project of Rarer Cancers , 2022 .

[2]  Peizhan Chen,et al.  Meta-analysis of vitamin D, calcium and the prevention of breast cancer , 2010, Breast Cancer Research and Treatment.

[3]  J. Barrett,et al.  Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Goodwin,et al.  Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Mohr,et al.  Vitamin D for cancer prevention: global perspective. , 2009, Annals of epidemiology.

[6]  V. Arndt,et al.  Meta‐analysis: longitudinal studies of serum vitamin D and colorectal cancer risk , 2009, Alimentary pharmacology & therapeutics.

[7]  S. Cremers,et al.  High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Hartge,et al.  A prospective investigation of serum 25‐hydroxyvitamin D and risk of lymphoid cancers , 2009, International journal of cancer.

[9]  J. Meyerhardt,et al.  Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Shanafelt,et al.  Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Drezner,et al.  Correlation among 25-hydroxy-vitamin D assays. , 2008, The Journal of clinical endocrinology and metabolism.

[12]  T. Shanafelt,et al.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential , 2008, British journal of haematology.

[13]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[14]  R. Recker,et al.  Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. , 2007, The American journal of clinical nutrition.

[15]  D. Neuberg,et al.  Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Shanafelt,et al.  Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Yan Liu,et al.  Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. , 2006, Journal of the National Cancer Institute.

[18]  M. Holick.  High prevalence of vitamin D inadequacy and implications for health. , 2006, Mayo Clinic proceedings.

[19]  R. Heaney.  The Vitamin D requirement in health and disease , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  Edward Giovannucci,et al.  Vitamin D and prevention of colorectal cancer , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  E. Stauber,et al.  Proteomics of Chlamydomonas reinhardtii Light-Harvesting Proteins , 2003, Eukaryotic Cell.

[22]  J. O'fallon,et al.  Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia , 2003, British journal of haematology.

[23]  C. Fegan,et al.  The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. , 2003, Blood.

[24]  A. Tefferi,et al.  Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia , 2001, British journal of haematology.

[25]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[26]  H. Muller-Hermelink,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[28]  Paul H. C. Eilers,et al.  Flexible smoothing with B-splines and penalties , 1996 .

[29]  G. Omenn,et al.  The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. , 1994, Cancer research.

[30]  T. Hickish,et al.  The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. , 1993, British Journal of Cancer.

[31]  D. Cunningham,et al.  Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. , 1991, British Journal of Cancer.

[32]  P. Ueland,et al.  Phenotypic markers in chronic lymphocytic leukemia. , 1986 .

[33]  D. Emerson,et al.  Linkage between surface immunoglobulin and cytoskeleton of B lymphocytes may involve Gc protein , 1983, Nature.

[34]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.

[35]  F. Oksman,et al.  Binding of the apo and holo forms of the serum vitamin D-binding protein to human lymphocyte cytoplasm and membrane by indirect immunofluorescence. , 1981, Immunology letters.

[36]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[38]  ONSTANZE,et al.  GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .

[39]  D. Bikle.  Nonclassic actions of vitamin D. , 2009, The Journal of clinical endocrinology and metabolism.

[40]  J. Cerhan,et al.  Personal sun exposure and risk of non Hodgkin lymphoma: A pooled analysis from the Interlymph Consortium , 2008, International journal of cancer.

[41]  P. Taylor,et al.  Clinical trials of vitamin and mineral supplements for cancer prevention. , 2007, The American journal of clinical nutrition.

[42]  C. Carlberg.  Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[43]  E. Gunter,et al.  Hypovitaminosis D in medical inpatients. , 1998, The New England journal of medicine.

[44]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[45]  R. Galbraith,et al.  Phenotypic markers in chronic lymphocytic leukemia. , 1986, The New England journal of medicine.

[46]  P. Arnaud,et al.  Gc (vitamin D binding protein) binds to cytoplasm of all human lymphocytes and is expressed on B-cell membranes. , 1984, Clinical immunology and immunopathology.

[47]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .